ABG
XENE icon

Ally Bridge Group’s Xenon Pharmaceuticals XENE Stock Holding History

Ally Bridge Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-69,603
Closed -$2.34M – 37
2025
Q1 		$2.34M Sell
69,603
-59,688
-46% -$2.27M 2.11% 18
2024
Q4 		$5.07M Sell
129,291
-82,500
-39% -$3.41M 4.35% 5
2024
Q3 		$8.34M Buy
211,791
+42,422
+25% +$1.71M 4.46% 7
2024
Q2 		$6.6M Sell
169,369
-140,000
-45% -$5.6M 3.93% 12
2024
Q1 		$13.3M Buy
309,369
+67,408
+28% +$3.1M 7.4% 4
2023
Q4 		$11.1M Sell
241,961
-25,000
-9% -$883K 6.64% 5
2023
Q3 		$9.12M Hold
266,961
– – 10.7% 2
2023
Q2 		$10.3M Hold
266,961
– – 12.45% 3
2023
Q1 		$9.55M Buy
+266,961
New +$9.86M 12.52% 2

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ally Bridge Group's XENE Position: Q2 2025 in Review

Ally Bridge Group sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 69,603 shares — an estimated $2.34M sold.

Ally Bridge Group first reported a position in XENE in Q1 2023 and held it in 9 quarters. The position peaked at $13.3M in Q1 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Ally Bridge Group reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ally Bridge Group sold 69,603 Xenon Pharmaceuticals shares in Q2 2025, an estimated $2.34M.
  • Ally Bridge Group first reported a position in Xenon Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Ally Bridge Group's Xenon Pharmaceuticals position peaked at $13.3M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.